More on Alexion (ALXN -1.2%) Q1: Net profit +69% to $45.4M, boosted by strong sales of its...

|About: Alexion Pharmaceuticals, ... (ALXN)|By:, SA News Editor

More on Alexion (ALXN -1.2%) Q1: Net profit +69% to $45.4M, boosted by strong sales of its Soliris drug for the treatment of a rare blood disorder. Alexion also ups its guidance and now expects FY EPS of $1.65-$1.75 vs. $1.60-$1.70 prior and revenue of $1.065B-$1.085B vs $1.04B-$1.07B. Analysts forecast EPS of $1.74 on revenue of $1.07B.